Figures S1 - S6 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)